{"summary":"Pharmaceutical Sciences professional with experience developing therapeutic products from pre-clinical through to registration and life-cycle management.  Past projects include targeted therapies, immuno-oncology, antibody-drug conjugates (ADCs) and cell-based therapies. Successfully implemented innovative regulatory strategies, including fast track, breakthrough therapy, and orphan drug designations, new molecular entity accelerated approvals, marketing application supplements, companion diagnostic co-development, and novel-novel combination drug development.","lastName":"Jazayeri","objectUrn":"urn:li:member:56593435","geoRegion":"Collegeville, Pennsylvania, United States","fullName":"Jonathan Jazayeri","firstName":"Jonathan","currentPositions":[{"companyName":"Kite Pharma","description":"- Develop and implement regulatory strategies for product development \n- Represent the regulatory function on cross-functional development teams\n- Provide regulatory guidance and strategy including identifying and assessing regulatory risks, mitigations, and contingencies\n- Plan, prepare, and review submissions to regulatory authorities including FDA, EMA and other national authorities to support the conduct of clinical trials and approval of marketing applications (IND, CTA, BLA, MAA) throughout the lifecycle of assigned projects\n- Lead and oversee regulatory activities for assigned projects in line with US, European, ICH, and other applicable requirements to ensure compliance\n- Manage the regulatory aspects of products and projects including achievement of timelines and deliverables\n- Ensure that regulatory documents are accurate, complete and verifiable, and confirm compliance with regulatory requirements\n- Serve as the Global Regulatory Leader (GRL) for assigned Regulatory Project Teams to form global strategies and advise the US Regulatory Lead (USRL) in the development of US regulatory approaches and execution of US filings\n- Supervise, analyze, and disseminate intelligence on matters that may affect ongoing development programs\n- Provide interpretation of and advice regarding regulations, directives, and guidance\n- Prepare meeting requests, briefing documents, coordinate and prepare teams for meetings, and collaborate with regulatory authorities; be primary liaison for day-to-day interactions\n- Coordinate responses to requests for information from regulatory authorities\n- Train, manage, and mentor other regulatory affairs personnel\n- Work externally to engage in regulatory policy initiatives","title":"Executive Director, Global Regulatory Affairs","companyUrnResolutionResult":{"website":"http:\/\/www.kitepharma.com","formattedRevenue":{"unit":"MILLION","amount":22.2,"currencyCode":"USD"},"industry":"Biotechnology Research","employeeCountRange":"1001-5000","headquarters":{"geographicArea":"California","country":"United States","city":"Santa Monica","postalCode":"90404","line1":"2400 Broadway"},"revenue":{"amount":"2.217E+7","currencyCode":"USD"},"flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/kite-pharma-inc-\/"},"companyUrn":"urn:li:fs_salesCompany:5807055","tenureAtCompany":{"numYears":3,"numMonths":4},"startedOn":{"month":2,"year":2021}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAANfjBsBYyskGpnCrUoRcX6DAFYkmKndzWs,NAME_SEARCH,HqwJ)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1571116834764?e=1723075200&v=beta&t=5RxNIsDavgmocVlbhdXL8LenV4aK7cqVAfa2u3JA7zs","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1571116834735?e=1723075200&v=beta&t=WlOFSzy2opcq782NyM05aBCEcTheiqnmYRg_hqqHCWA","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1571116834938?e=1723075200&v=beta&t=HKuTsfWWOJvv7e0TZ1_JKC2gn7qZm3Ct6nNh7pojXkE","height":400},{"width":400,"fileIdentifyingUrlPathSegment":"800_800\/0\/1571116835456?e=1723075200&v=beta&t=5swN2d7CjvVjUUBQIzcCC5GddCrcZOFmzXSHqzrp748","height":400}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/C4E03AQF-3G2v_0Y8bw\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"endedOn":{"year":2011},"degree":"Doctorate","eduId":41504860,"schoolUrn":"urn:li:fs_salesSchool:3084","school":"urn:li:fs_salesSchool:3084","fieldsOfStudy":["Pharmacy"],"startedOn":{"year":2007}},{"endedOn":{"year":2011},"degree":"Masters of Science","eduId":65417474,"fieldsOfStudy":["Regulatory Science"],"schoolName":"University of Southern California School of Pharmacy","startedOn":{"year":2007}},{"endedOn":{"year":2007},"degree":"Bachelor of Science","eduId":39446434,"schoolUrn":"urn:li:fs_salesSchool:5372","school":"urn:li:fs_salesSchool:5372","fieldsOfStudy":["Pharmacology"],"startedOn":{"year":2003}}],"skills":[{"numOfEndorsement":19,"name":"Clinical Research"},{"numOfEndorsement":32,"name":"Oncology"},{"numOfEndorsement":37,"name":"Regulatory Affairs"},{"numOfEndorsement":41,"name":"Clinical Trials"},{"numOfEndorsement":14,"name":"FDA"},{"numOfEndorsement":11,"name":"Pharmacology"},{"numOfEndorsement":22,"name":"Pharmaceutical Industry"},{"numOfEndorsement":16,"name":"Biotechnology"},{"numOfEndorsement":4,"name":"Lifesciences"},{"numOfEndorsement":3,"name":"Cell Culture"},{"numOfEndorsement":9,"name":"Clinical Development"},{"numOfEndorsement":3,"name":"Immunology"},{"numOfEndorsement":4,"name":"Cancer"},{"numOfEndorsement":7,"name":"Pharmacokinetics"},{"numOfEndorsement":5,"name":"Medical Writing"},{"numOfEndorsement":4,"name":"Pharmacists"},{"numOfEndorsement":3,"name":"Diabetes"},{"numOfEndorsement":4,"name":"Validation"},{"numOfEndorsement":5,"name":"Managed Care"},{"numOfEndorsement":8,"name":"In Vitro"},{"numOfEndorsement":3,"name":"IND"},{"numOfEndorsement":3,"name":"Clinical Pharmacology"},{"numOfEndorsement":4,"name":"Pharmacy"},{"numOfEndorsement":4,"name":"U.S. Food and Drug Administration (FDA)"},{"numOfEndorsement":3,"name":"Life Sciences"}],"numOfConnections":2009,"patents":[],"headline":"Executive Director, Global Regulatory Affairs at Kite Pharma","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/jonathan-jazayeri-9b7b5216","organizations":[],"location":"Collegeville, Pennsylvania, United States","publications":[],"positions":null,"posts":[{"createdAt":1716487500000,"insightId":"5d5343f4-9db5-421d-a3ca-bbc0a971e4db","activityUnion":{"postActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"VIDEO","thumnailUrl":"https:\/\/dms.licdn.com\/playlist\/vid\/D4E05AQF4MNBn8Mbg-Q\/videocover-firstframe-low\/0\/1716487504932?e=1717977600&v=beta&t=CM7i0LrUaT_xyr8Y29u9-VM9MTU3lou9uJf3Vd532D4"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":42},{"type":"PRAISE","count":9},{"type":"EMPATHY","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:ugcPost:7199470368531566592","threadUrn":"urn:li:ugcPost:7199470368531566592","reactionsCount":53,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7199470368531566592","message":{"attributes":[{"start":176,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:gileadlife"}}},{"start":188,"length":15,"value":{"com.linkedin.common.MemberAttributedEntity":{"member":"urn:li:member:819961884"}}}],"text":"A big welcome to our Summer 2024 interns. Get ready to dive into a season of innovation and discovery.\u00a0We're thrilled to have you join our team and can't wait to see you grow. #GileadLife Arianna Beltran"},"entityUrn":"urn:li:ugcPost:7199470368531566592"}}},{"createdAt":1712594040000,"insightId":"2b843f5c-01e5-4902-b34b-c6e9d934c7c3","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQGITpc_xDYbqg\/articleshare-shrink_800\/0\/1712871143681?e=1717977600&v=beta&t=4xbCJp1ZC9CPinOWTA1csZhWk1GLXYM1WN-sySbN2tQ","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQGITpc_xDYbqg\/articleshare-shrink_800\/0\/1712871143681?e=1717977600&v=beta&t=4xbCJp1ZC9CPinOWTA1csZhWk1GLXYM1WN-sySbN2tQ"}]},"description":"Significant advancements have been made in the field of cellular therapy as anti-cancer treatments, with the approval of chimeric antigen receptor (CAR)-T cell therapies and the development of other genetically engineered cellular therapies. CAR-T...","fullText":"Significant advancements have been made in the field of cellular therapy as anti-cancer treatments, with the approval of chimeric antigen receptor (CAR)-T cell therapies and the development of other genetically engineered cellular therapies. CAR-T cell therapies have demonstrated remarkable clinical outcomes in various hematological malignancies, establishing their potential to change the current cancer treatment paradigm. Due to the increasing importance of genetically engineered cellular therapies in the oncology treatment landscape, implementing strategies to expedite development and evidence generation for the next generation of cellular therapy products can have a positive impact on patients. We outline a risk-based methodology and assessment aid for the data extrapolation approach across related genetically engineered cellular therapy products. This systematic data extrapolation approach has applicability beyond CAR-T cells and can influence clinical development strategies for a variety of immune therapies such as T cell receptor (TCR) or genetically engineered and other cell-based therapies (e.g., tumor infiltrating lymphocytes, natural killer cells and macrophages). By analyzing commonalities in manufacturing processes, clinical trial designs, and regulatory considerations, key learnings were identified. These insights support optimization of the development and regulatory approval of novel cellular therapies. The field of cellular therapy holds immense promise in safely and effectively treating cancer. The ability to extrapolate data across related products presents opportunities to streamline the development process and accelerate the delivery of novel therapies to patients.","resolvedUrl":"https:\/\/www.isct-cytotherapy.org\/article\/S1465-3249(24)00097-5\/fulltext","title":"Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products","sourceDomain":"isct-cytotherapy.org"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":49},{"type":"PRAISE","count":9}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7183140144491732992","threadUrn":"urn:li:activity:7183140144491732992","reactionsCount":58,"commentsCount":4,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7183140144080662528","message":{"attributes":[],"text":"An interesting article on the concept of data extrapolation across next generation cell therapy products.  If you pay close attention to the authors you might find a familiar name :)"},"entityUrn":"urn:li:share:7183140144080662528"}}},{"createdAt":1712593860000,"insightId":"49b07af3-db32-4245-bc83-610b5fd368eb","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQGITpc_xDYbqg\/articleshare-shrink_800\/0\/1712871143681?e=1717977600&v=beta&t=4xbCJp1ZC9CPinOWTA1csZhWk1GLXYM1WN-sySbN2tQ","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQGITpc_xDYbqg\/articleshare-shrink_800\/0\/1712871143681?e=1717977600&v=beta&t=4xbCJp1ZC9CPinOWTA1csZhWk1GLXYM1WN-sySbN2tQ"}]},"description":"Significant advancements have been made in the field of cellular therapy as anti-cancer treatments, with the approval of chimeric antigen receptor (CAR)-T cell therapies and the development of other genetically engineered cellular therapies. CAR-T...","fullText":"Significant advancements have been made in the field of cellular therapy as anti-cancer treatments, with the approval of chimeric antigen receptor (CAR)-T cell therapies and the development of other genetically engineered cellular therapies. CAR-T cell therapies have demonstrated remarkable clinical outcomes in various hematological malignancies, establishing their potential to change the current cancer treatment paradigm. Due to the increasing importance of genetically engineered cellular therapies in the oncology treatment landscape, implementing strategies to expedite development and evidence generation for the next generation of cellular therapy products can have a positive impact on patients. We outline a risk-based methodology and assessment aid for the data extrapolation approach across related genetically engineered cellular therapy products. This systematic data extrapolation approach has applicability beyond CAR-T cells and can influence clinical development strategies for a variety of immune therapies such as T cell receptor (TCR) or genetically engineered and other cell-based therapies (e.g., tumor infiltrating lymphocytes, natural killer cells and macrophages). By analyzing commonalities in manufacturing processes, clinical trial designs, and regulatory considerations, key learnings were identified. These insights support optimization of the development and regulatory approval of novel cellular therapies. The field of cellular therapy holds immense promise in safely and effectively treating cancer. The ability to extrapolate data across related products presents opportunities to streamline the development process and accelerate the delivery of novel therapies to patients.","resolvedUrl":"https:\/\/www.isct-cytotherapy.org\/article\/S1465-3249(24)00097-5\/fulltext","title":"Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products","sourceDomain":"isct-cytotherapy.org"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":3}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7183139330289209344","threadUrn":"urn:li:activity:7183139330289209344","reactionsCount":3,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7183139329739784192","message":{"attributes":[],"text":"An interesting article on the concept of data extrapolation across next generation cell therapy products. If you look close at the authors you might see a familiar name :)"},"entityUrn":"urn:li:share:7183139329739784192"}}},{"createdAt":1717181400000,"insightId":"9cfd590b-3217-4bc7-b9b5-58196eb67d82","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7202373510965473280,7202380821540798464)","threadUrn":"urn:li:ugcPost:7202373510965473280","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Tony!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7202373510965473280"}}},{"createdAt":1716492720000,"insightId":"0ddc9f51-5f7f-4f9a-9158-c6f794d5d50a","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7199489447317389315,7199492464808738816)","threadUrn":"urn:li:activity:7199489447317389315","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"welcome back"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7199489447317389315"}}},{"createdAt":1715957580000,"insightId":"0ff7417d-aec5-4113-9c80-c5aff9d77f97","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7196880388869287936,7197247881274159104)","threadUrn":"urn:li:ugcPost:7196880388869287936","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Jamie!  Hope to see you at an F1 race weekend :)"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7196880388869287936"}}},{"createdAt":1713977760000,"insightId":"ca70380c-e522-4dfb-a921-00103679a16e","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"EMPATHY","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7188707384746217473,7188943861103185922)","threadUrn":"urn:li:activity:7188707384746217473","reactionsCount":1,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"They are lucky to have you!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7188707384746217473"}}},{"createdAt":1711991040000,"insightId":"9e9c9abd-9e81-4216-941a-536baede4574","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7180380769163341824,7180610907301924865)","threadUrn":"urn:li:ugcPost:7180380769163341824","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Renee!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7180380769163341824"}}},{"createdAt":1710384960000,"insightId":"e53a17e4-3605-4523-9b9a-bb9765e13ed6","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7173713560760467456,7173874583744315392)","threadUrn":"urn:li:ugcPost:7173713560760467456","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats Joshua!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7173713560760467456"}}}]}